Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
Abstract
Background: Despite high initial response rates, most patients (pts) with SCLC relapse soon after first-line (1L) treatment (tx), with limited tx options and a poor prognosis. Nivo is approved in the US for tx of metastatic SCLC with progression after platinum-based chemo and ≥1 other line of tx. We report results from CheckMate 331 (NCT02481830), a global, open-label, phase 3 trial of nivo vs chemo in pts with relapsed SCLC after 1L...
Paper Details
Title
Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331
Published Date
Dec 1, 2018
Journal
Volume
29
Pages
x43 - x43
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History